Unesbulin
- Generic Name
- Unesbulin
- Drug Type
- Small Molecule
- Chemical Formula
- C19H13F5N6
- CAS Number
- 1610964-64-1
- Unique Ingredient Identifier
- Z4HZ70S62Q
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
- Conditions
- Leiomyosarcoma
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 360
- Registration Number
- NCT05269355
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸The Ohio State University (OSU), Columbus, Ohio, United States
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT03761095
- Locations
- 🇺🇸
John Hopkins, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Washington University Medical Campus, Saint Louis, Missouri, United States
A Phase 1b Study of PTC596 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
- Conditions
- High Grade GliomaDiffuse Intrinsic Pontine Glioma
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT03605550
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 27
- Registration Number
- NCT03206645
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
PTC596 in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT02404480
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.